Medtimo Inc news
- New Calibration Tubes, in Three Sizes, Will Simplify Gastric and Bariatric Procedures Including Laparoscopic Sleeve Gastrectomy, Gastric Bypass and Gastric Banding
- Company to Introduce Product at IFSO 2022 World Congress in August; Sales to Commence in September
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the winners of its 2017 weight loss contest, which recognizes patients for their successful weight loss with the ReShape Balloon™.
The contest winner lost a total of 80 pounds, or 41% total weight loss (TWL), with 60 pounds, or 28% TWL, lost during the 6-month ReShape Balloon implant period, followed by continued weight loss of the r
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announces that the United States Patent and Trademark Office (“USPTO”) has issued an Issue Notification for U.S. Patent Number 10010441 entitled “Gastric Restriction Device for Treating Obesity,” which covers a patent application regarding the Company’s Gastric Vest System (the “ReShape Vest”). Barring any unforesee
Researchers have found that when one member of a couple commits to losing weight, the chances are good their partner will lose weight too, even if they are not actively participating in a weight loss intervention.
The study followed 130 couples—defined as partners living together—for six months, during which one person in each relationship followed a weight loss prog
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced an exclusive federal government business channel sales agreement with Academy Medical, LLC to sell its ReShape Balloon™ and ReShape vBloc products to U.S. Department of Defense (DoD) medical facilities.
Through this agreement, the ReShape Balloon and ReShape vBloc are both now approved products for sale into DoD medical facilities. T
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company and its products will be discussed during the Metabolic and Bariatric Sessions of the Minimally Invasive Surgery Symposium (MISS) taking place in Las Vegas from March 6-9, 2018.
Details of the presentations are as follows:
Friday, March 9, 2018: 11:00 AM:
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases announced today that it has received a significant order for its ReShape® Integrated Dual Balloon System from Al Zahrawi Medical a healthcare focused company specializing in medical, surgical, diagnostic and analytical lab and nuclear medicine supplies with presence throughout the United Arab Emirates (UAE) and Qatar. This orde
A new study published by The Obesity Society finds that being overweight can lead to financial costs. This is largely due to the need for more medical costs and loss of productivity caused by obesity.
The research suggests that a 20-year-old who goes from being obese (BMI of 30 or higher) to overweight (BMI of 25 to 29.9) would save an average of $17,6
ReShape Medical® today announced that it has completed a Series D financing of $38 million led by HealthCor Partners Management, L.P. with participation from Endeavour Vision SA and existing investors, SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners and Venture Investors. The announcement follows the recent approval of the ReShape™ Integrated Dual Balloon System, a first-of-its-kind non-surgical weight loss procedure, by the U.S